Cal. Code Regs. Tit. 8, div. 1, ch. 4, subch. 7, grp. 16, art. 110, app B

Current through Register 2024 Notice Reg. No. 39, September 27, 2024
Appendix B - Supplemental Medical Information

(1) When required tests under Section 5215(k)(2) reveal abnormalities, the tests should be repeated as soon as practicable within 30 days. If the tests remain abnormal, consideration should be given to withdrawing the employee from contact with 4,4'-methylenebis(2-chloroaniline) while a more comprehensive examination is made.

(2) Additional tests that may be useful;

(A) Pulmonary system

1. Sputum cytology

2. Bronchoscopy with bronchial washings for cytology and tissue biopsy.

3. Computerized axial tomography with or without use of a contrast medium.

(B) Liver

1. Liver scan

2. Percutaneous liver biopsy

3. Hepatic angiography

(C) Urinary system

1. Urine cytology, 24-hour specimen

2. Blood urea nitrogen (BUN)

3. Serum creatinine

4. Creatinine clearance

5. Radioactive renogram

6. Intravenous pyelogram (IVP)

7. Cystoscopy with retrograde pyelogram and/or urinary bladder biopsy, as indicated.

8. Percutaneous renal biopsy.

(D) Breasts

1. Mammography

2. Breasts biopsy

(3) Known toxicity of 4,4'-methylenebis(2-chloroaniline)

(A) Pulmonary carcinoma*

(B) Malignant tumors of the liver*

(C) Carcinoma of the breast*

(D) Carcinoma of the urinary bladder*

(E) Kidney irritation

(F) Methemoglobinemia*

*Observed in experimental animals only

(4) Routes of absorption

(A) Skin (primary)

(B) Inhalation (secondary)

(C) Ingestion (minor)

Cal. Code Regs. Tit. 8, div. 1, ch. 4, subch. 7, grp. 16, art. 110, app B